Skip to main content
ProMIS Neurosciences Inc. logo

ProMIS Neurosciences Inc. — Investor Relations & Filings

Ticker · PMN ISIN · CA74346M1095 LEI · 5299007HZF79F9IAXI53 US Professional, scientific and technical activities
Open in API
Filings indexed 333 across all filing types
Latest filing 2024-09-25 Director's Dealing
Country CA Canada
Listing US PMN

About ProMIS Neurosciences Inc.

https://www.promisneurosciences.com/

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company focused on the discovery and development of selective antibody therapeutics for neurodegenerative and other misfolded protein diseases. The company leverages a proprietary technology platform to design and generate antibodies that selectively target toxic oligomers, which are key drivers of diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), and multiple system atrophy (MSA). Its lead product candidate, PMN310, is in clinical development for Alzheimer's disease. The company's approach aims to provide effective treatments while potentially reducing side effects associated with less specific therapies.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2024-09-25 English
OWNERSHIP DOCUMENT
Director's Dealing
2024-09-18 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It includes information about a special shareholder meeting, voting instructions, and proposals to be voted on. The document is titled 'Definitive Additional Materials' related to the proxy statement, indicating it supplements the proxy materials rather than being the proxy statement itself. The content focuses on voting matters and meeting logistics rather than financial results or management discussion. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains substantive proxy solicitation content, not just an announcement of availability, so it is not a Report Publication Announcement (RPA).
2024-09-09 English
DEF 14A
Proxy Solicitation & Information Statement
2024-09-09 English
Regulatory Filings 2024
Regulatory Filings
2024-09-09 English
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the SEC Division of Corporation Finance requesting acceleration of the effective date for a Registration Statement on Form S-3. It references Rule 461 under the Securities Act of 1933 and includes formal communication from the company's interim CEO and legal counsel. The content is a regulatory procedural request related to a registration statement, not a financial report, earnings release, or other detailed corporate filing. The document length is short (1743 characters), and it is clearly an official regulatory filing communication. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2024-09-04 English

Browse filings by year

21 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.